Search PubMedSearch

PubMed · 622518

Indications for pulmonary function testing.

Abstract

Pulmonary function testing is needed to determine the pathophysiology present in the patient with cardiopulmonary disease. Blood gases and pH should be obtained during emergency situations and during cranial, thoracic, and extensive cervical or abdominal surgery. Lung function tests can be divided in global such as spirometry and diffusing capacity which study the ventilation and transfer of gases and regional determinations of ventilation and perfusion. Both types of tests complement each other and should be used together. The spirometry should consist at least of determination of the vital capacity and is determined in the first second to ascertain if there is obstructive lung disease. Some tests such as flow-volume curves, alveolar-arterial gradients and closing volume are very useful to detect early pulmonary disease before any symptoms or findings are present. This is probably one of the most important medical indications for pulmonary function testing. Before certain types of surgery pulmonary function testing is indicated; if the spirometry and diffusing capacity tests are normal, there is no pulmonary contraindication for the planned surgery. In chest surgery if there is significant compromise of the spirometry and diffusing capacity regional lung function tests are indicated to study the pathophysiology at regional level, thus trying to circumscribe the lung resection to the diseased areas.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

V Lopez-Majano, G Renzi. 1978. Indications for pulmonary function testing.. https://doi.org/10.1159/000193859

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

High frequency oscillatory ventilation and extracorporeal membrane oxygenation in severe persistent pulmonary hypertension of the newborn.

We report on 50 term and near-term neonates (birth weight greater than 1800 g, gestational age greater than 33 weeks) with severe persistent pulmonary hypertension of the newborn (PPHN), referred to us from January 1987 to July 1991 after failure of maximum conventional treatment. All infants had paO2 less than 45 mm Hg when ventilated with peak inspiratory pressure greater than 38 cm H2O and FiO2 = 1.0, hence meeting entry criteria for extracorporeal membrane oxygenation (ECMO). High frequency oscillatory ventilation (HFOV) was tried in all patients. If sufficient oxygenation could not be achieved (paO2 less than 40 mm Hg for at least 2 h), ECMO therapy was begun, which was the case in 25 children. Neonates responding to HFOV (n = 25) were of a slightly younger gestational age (37.0 weeks vs 38.8 weeks, P less than 0.05), had higher Apgar scores and were less hypoxaemic before HFOV (paO2 36.6 mm Hg vs 28.8 mm Hg, P less than 0.01); during HFOV there was a significant rise in paO2 (greater than 150 mm Hg; P less than 0.001) and a fall in pCO2 to 21.6 mm Hg (P less than 0.001). Due to air leaks, which was the main complication of HFOV (52%), ECMO therapy had to be begun in two additional infants after an initial positive effect. HFOV tended to be successful in cases of primary PPHN, meconium aspiration and sepsis, but not in infants with lung hypoplasia as a result of diaphragmatic hernia or other reasons. Success or failure of HFOV could not be reliably predicted by any parameter.(ABSTRACT TRUNCATED AT 250 WORDS)

Blood Gas Analysis